Executive Summary
The US M&A landscape on November 10, 2026, is dominated by SPAC activity, with seven of eight filings involving blank-check companies or de-SPAC transactions, signaling a resurgence in SPAC-led M&A.
A clear theme is the aggressive growth targets set by de-SPAC targets: BHAV's Nemi aims for $120M ARR (32x current run-rate) and Bunker Hill projects 5 Moz AgEq annual production, though both rely heavily on acquisitions or analyst projections. Deal structures are increasingly complex, featuring multi-step mergers, reverse recapitalizations, and cross-border continuances (Globa Terra/Nature's Ledger, InMed/Mentari). Capital raising is prominent, with InMed's $490M pre-closing financing and Iron Horse's $5M bridge round, while SPAC sponsors are extending deadlines and increasing notes (Texas Ventures, Globa Terra). Valuation gaps are evident: InMed's legacy value of $5.6M versus $478M pro forma cash highlights the near-total change of control. Overall, the filings reflect a market hungry for growth stories, but with heightened execution risk and reliance on favorable financing conditions.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US Merger & Acquisition SEC Filings digest from November 09, 2026.
Investment Signals (8)
- BHAV Acquisition Corp ↓ (SPECULATIVE BULLISH)▲
Nemi targets $120M Operating ARR within 12 months post-closing, a 32x increase from Q3 2026 run-rate of ~$3.7M, with ~6x growth to ~$20M at closing; however, ~25% ($30M) of target depends on unsigned acquisitions and $100M+ LOIs are non-binding
- InMed Pharmaceuticals ↓ (BULLISH)▲
Completed reverse merger with Mentari Therapeutics, which brought $490M in gross proceeds ($290M first tranche + $200M second tranche), resulting in pro forma cash of $478.1M; former Mentari holders own ~99% of combined company, signaling a near-total change of control and potential for new strategic direction in migraine therapies
- Bunker Hill Mining Corp ↓ (BULLISH)▲
Completed acquisition of Silver47, creating a combined entity with pro forma market cap of US$158M and aggregate resources of 80 Moz AgEq M&I plus 308 Moz AgEq inferred across four U.S. projects; commercial production targeted by end of 2026, with 2027 output of +2,500 koz AgEq based on analyst consensus
-
ELECTRA AI secured ~$5M in new bridge financing to support commercial execution, and the Form S-4 Amendment No. 1 includes unaudited financials for H1 2026; deal expected to close in Q1 2027, listing on Nasdaq under 'AIBR' [NEUTRAL/BULLISH]
- Globa Terra Acquisition Corp ↓ (NEUTRAL)▲
Entered into a Business Combination Agreement with Nature's Ledger Inc., structured as a multi-step SPAC merger involving a new Cayman Pubco and continuance to Alberta; while terms are undisclosed, the cross-border structure may unlock value in the natural products sector
- Texas Ventures Acquisition III Corp ↓ (NEUTRAL)▲
Sponsor increased promissory note to $750,000 from $250,000, with conversion at $10.00 per unit; this signals sponsor commitment to the deal but also highlights the need for additional capital to sustain operations
- Live Oak Acquisition Corp. VI ↓ (NEUTRAL)▲
Announced unit separation effective November 13, 2026, allowing shares (LOVI) and warrants (LOVIW) to trade separately; this is a routine post-IPO event that may increase liquidity and trading volume
- Globa Terra Acquisition Corp ↓ (NEUTRAL)▲
Extended initial business combination deadline to November 9, 2026, with potential for eight additional one-month extensions; the extension requires a deposit of US$0.03 per public share, indicating ongoing efforts to complete a deal
Risk Flags (7)
- BHAV Acquisition Corp↓ [HIGH RISK]▼
~25% ($30M) of the $120M ARR target depends on acquisitions not yet signed, and $100M+ of LOIs are non-binding; Nemi's operations are geographically concentrated in India, and its EV business is only expected to become profitable in 2027
- InMed Pharmaceuticals↓ [HIGH RISK]▼
Combined company carries an accumulated deficit of $50.2M, and legacy InMed was valued at only $5.6M on net cash of $(4.4)M; the reverse merger resulted in ~99% ownership by former Mentari holders, leaving legacy InMed shareholders with ~1%
- Bunker Hill Mining Corp↓ [HIGH RISK]▼
The combined entity remains pre-commercial at the Bunker Hill Mine, with commercial production targeted by end of 2026; the +5 Moz AgEq annual production target is aspirational, and 2027 output of +2,500 koz AgEq is based on analyst consensus, not company guidance
- Globa Terra Acquisition Corp↓ [HIGH RISK]▼
No transaction value, PIPE size, or financial terms were disclosed in the 8-K; completion is subject to shareholder approval, PIPE funding, and Nasdaq listing conditions, with significant execution risk
- Texas Ventures Acquisition III Corp↓ [MEDIUM RISK]▼
The company has no specific business combination target and is relying on a $750,000 note from its sponsor to fund operations; the note is non-interest bearing and convertible at $10.00 per unit, which could dilute existing shareholders
- Iron Horse Acquisition II Corp↓ [MEDIUM RISK]▼
No revenue, profitability, or valuation figures were disclosed in the filing; the deal is subject to SEC effectiveness and shareholder approvals, and closing is targeted for Q1 2027, leaving ample time for potential delays
- Live Oak Acquisition Corp. VI↓ [LOW RISK]▼
The company has not yet announced a business combination target, and the unit separation is a routine event that does not indicate progress on a deal; investors may face opportunity cost
Opportunities (7)
- BHAV Acquisition Corp↓ (OPPORTUNITY)◆
If Nemi achieves its $120M ARR target, the combined company could be valued at a significant premium; the current run-rate of ~$3.7M implies a low base, and the EV business could become profitable in 2027, providing a catalyst
- InMed Pharmaceuticals↓ (OPPORTUNITY)◆
The $490M financing provides ample cash for the combined company to advance its migraine prevention therapies; the near-total change of control may bring new management expertise and strategic focus
- Bunker Hill Mining Corp↓ (OPPORTUNITY)◆
The combined company's resource base of 80 Moz AgEq M&I and 308 Moz AgEq inferred across four U.S. projects offers significant leverage to silver prices; commercial production at Bunker Hill Mine by end of 2026 could be a near-term catalyst
- Iron Horse Acquisition II Corp↓ (OPPORTUNITY)◆
ELECTRA AI's ~$5M bridge financing supports commercial execution, and the deal is expected to close in Q1 2027; the company operates in the AI/EV space, which could attract growth investors
- Globa Terra Acquisition Corp↓ (OPPORTUNITY)◆
The cross-border structure with Nature's Ledger Inc. may create a unique investment opportunity in the natural products sector; the continuance to Alberta could provide tax advantages
- Texas Ventures Acquisition III Corp↓ (OPPORTUNITY)◆
The increased sponsor note demonstrates commitment, and the conversion feature at $10.00 per unit could be attractive if the company announces a strong business combination target
- Live Oak Acquisition Corp. VI↓ (OPPORTUNITY)◆
The unit separation may increase liquidity and attract arbitrageurs; investors can now trade shares and warrants separately, potentially enhancing returns
Sector Themes (6)
- SPAC Resurgence◆
7 of 8 filings involve SPACs or de-SPAC transactions, indicating a revival in blank-check M&A activity; sponsors are extending deadlines (Globa Terra) and increasing notes (Texas Ventures) to sustain operations, while targets like Nemi and ELECTRA AI are using SPACs to access public markets [IMPLICATION: Increased competition for quality targets and potential dilution for SPAC shareholders]
- Aggressive Growth Targets◆
De-SPAC targets are setting ambitious projections: Nemi targets $120M ARR (32x current run-rate), Bunker Hill targets 5 Moz AgEq annual production, and InMed's Mentari brought $490M in financing; these targets often rely on acquisitions or analyst estimates rather than company guidance, raising execution risk [IMPLICATION: Investors should scrutinize the credibility of projections and the use of non-binding LOIs]
- Complex Deal Structures◆
Multi-step mergers, reverse recapitalizations, and cross-border continuances are common (Globa Terra/Nature's Ledger, InMed/Mentari, BHAV/Nemi); these structures can offer tax and regulatory benefits but also increase complexity and execution risk [IMPLICATION: Legal and regulatory hurdles may delay closings, and shareholders may face unfavorable terms]
- Capital Raising in De-SPACs◆
InMed's $490M pre-closing financing and Iron Horse's $5M bridge round highlight the need for capital to support commercial execution; PIPE financing is a common condition for closing (BHAV, Globa Terra) [IMPLICATION: Deals are increasingly reliant on external funding, which may be sensitive to market conditions]
- Resource Sector Consolidation◆
Bunker Hill's acquisition of Silver47 creates a combined entity with significant silver resources; the deal reflects consolidation in the mining sector as companies seek scale and diversification [IMPLICATION: Larger resource base may attract institutional investors and improve liquidity]
- Geographic Diversification◆
Nemi's operations are concentrated in India, while Globa Terra's target is based in Alberta; SPACs are increasingly looking outside the U.S. for targets, potentially offering growth opportunities but also introducing geopolitical and currency risks [IMPLICATION: Investors should assess country-specific risks and regulatory environments]
Watch List (8)
-
Form S-4 registration statement targeted for November 2026; closing targeted for Q1 2027, subject to shareholder approval, Nasdaq listing approval, and PIPE financing; watch for updates on acquisition LOIs and ARR progress [Date: November 2026]
-
Form S-4 Amendment No. 1 filed; deal expected to close in Q1 2027; watch for SEC effectiveness and shareholder vote, as well as commercial progress of ELECTRA AI [Date: Q1 2027]
-
Business Combination Agreement with Nature's Ledger Inc. announced; completion subject to shareholder approval, PIPE funding, and Nasdaq listing conditions; watch for disclosure of transaction terms and PIPE size [Date: TBD]
-
Commercial production at Bunker Hill Mine targeted by end of 2026; watch for production updates and resource expansion at Silver47 projects [Date: End of 2026]
-
Completed reverse merger with Mentari Therapeutics; watch for clinical trial updates for migraine prevention therapies and integration progress [Date: TBD]
-
Increased sponsor note to $750,000; watch for announcement of a business combination target and potential dilution from note conversion [Date: TBD]
-
Unit separation effective November 13, 2026; watch for trading liquidity and any announcement of a business combination target [Date: November 13, 2026]
-
Extended business combination deadline to November 9, 2026, with potential for further extensions; watch for trust account deposits and shareholder redemptions [Date: November 9, 2026]
Filing Analyses
(8)
10-11-2026
Globa Terra Acquisition Corporation (Nasdaq: GTERU) announced on November 8, 2026 that it entered into a Business Combination Agreement with Nature's Ledger Inc., an Alberta corporation, structured as a multi-step SPAC merger involving a new Cayman Pubco, a continuance to Alberta, and a plan of arrangement amalgamating Nature's Ledger with a Globa Terra subsidiary. Post-closing, Pubco will be the publicly traded parent and Nature's Ledger securityholders (including PIPE investors) will receive Pubco common shares. The filing is a Regulation FD disclosure only — no transaction value, PIPE size, or financial terms were disclosed, and completion remains subject to shareholder approval, PIPE funding, and Nasdaq listing conditions.
- · Business Combination Agreement dated November 8, 2026; 8-K filed November 10, 2026 under Items 7.01 and 9.01
- · Press Release attached as Exhibit 99.1
- · Transaction structure: (i) Globa Terra merges into new Cayman Pubco (SPAC Merger), (ii) Pubco continues out of Cayman into Alberta (Continuance), (iii) plan of arrangement under section 193 of the ABCA amalgamates Nature's Ledger, BCCo and AmalSub into Amalco, no earlier than the day after the Continuance
- · Nature's Ledger Inc. is incorporated under the Business Corporations Act (Alberta); BCCo is a British Columbia company to be continued under the ABCA
- · No transaction value, enterprise value, PIPE amount, or exchange ratio disclosed in this filing
- · Registration Statement on Form F-4 (or S-4) including proxy statement/prospectus to be filed; Globa Terra IPO Prospectus dated July 8, 2025 (filed July 9, 2025) and Form 10-K filed March 26, 2026 referenced
- · Closing conditions include Globa Terra shareholder approval, completion of PIPE financing, and Nasdaq listing of the Combined Company's securities
- · Risk factors cited include failure to complete the deal by the business combination deadline, high public shareholder redemptions, and failure to obtain/maintain Nasdaq listing
- · Globa Terra is an emerging growth company and a Cayman Islands exempted company headquartered in Miami, Florida
10-11-2026
BHAV Acquisition Corp (NASDAQ: BHAV) disclosed an investor presentation for its proposed business combination with Nemi Corp (parent of BNC Motors), under which BHAV will merge into Nemi subsidiaries and Nemi will become the listed company, with a Form S-4 targeted for November 2026 and closing targeted for Q1 2027. Nemi targets $120M of Operating ARR twelve months post-closing — roughly 32× its Q3 2026 run-rate of ~$3.7M and ~6× the ~$20M run-rate estimated at closing — but ~25% ($30M) of that target depends on acquisitions not yet signed, and the $100M+ of LOIs are non-binding. The deal requires a minimum-cash condition (waivable), BHAV shareholder approval, Nasdaq listing approval and PIPE financing, with a June 20, 2027 outside termination date; Nemi's operations are geographically concentrated in India and its EV business is only expected to become profitable in 2027.
- · Business combination agreement dated November 3, 2026; Form S-4 registration statement targeted for November 2026
- · Outside termination date of June 20, 2027 (or later extended date) if the deal has not closed
- · Closing conditions include BHAV shareholder approval, regulatory approvals, registration effectiveness, Nasdaq listing approval and a waivable minimum-cash condition
- · BHAV IPO prospectus dated March 18, 2026
- · Rupee amounts converted at ₹95.98/US$ (FBIL, September 30, 2026)
- · Jan–Sep 2026 revenue, cash use, and September 30, 2026 cash, working capital and net debt are from provisional unaudited Indian GAAP accounts
- · FY2025 revenue and FY2024/FY2025 gross margins derived from audited consolidated financial statements reporting a single operating segment
- · Operating ARR defined as latest quarter's external revenue × 4, not contracted or recurring revenue
- · Nemi's EV business expected to become profitable in 2027
- · Risks cited include geographic concentration in India, shareholder redemptions, PIPE size uncertainty and better-capitalized competition
10-11-2026
InMed Pharmaceuticals completed a reverse-merger with Mentari Therapeutics on November 6, 2026, with Mentari surviving as a wholly owned subsidiary and the combined entity renamed Mentari Therapeutics, Inc., now led by Mentari's management and focused on migraine prevention therapies. The deal was paired with a Mentari Pre-Closing Financing totaling $490.0 million in gross proceeds ($290.0 million first tranche plus $200.0 million second tranche), and under the 0.20065 exchange ratio former Mentari holders own approximately 99.0% of the combined company while legacy InMed holders are diluted to roughly 1.0%. Pro forma combined cash is $478.1 million against total assets of $478.8 million, but the combined company carries an accumulated deficit of $50.2 million and legacy InMed was valued at only $5.6 million on net cash of $(4.4) million, underscoring the near-total change of control.
- · Merger Agreement signed May 19, 2026 and amended July 6, 2026; Pre-Closing Financing amended July 22, 2026 to add the $200.0M second tranche
- · Merger structured as two-step merger: First Merger (Mentari into Indigo Merger Sub Corp) followed by Second Merger (Mentari into Indigo Merger Sub II, LLC)
- · Merger accounted for as a reverse recapitalization under U.S. GAAP
- · Pro forma balance sheet as of June 30, 2026; pro forma statements of operations for six months ended June 30, 2026 and year ended December 31, 2025
- · Mentari inception date June 13, 2025; audited financials cover period from inception through December 31, 2025
- · Pro forma adjustments include $439.3M cash infusion, $24.0M transaction costs, and $40.9M reclassification of InMed common stock to accumulated deficit
- · Legacy InMed out-of-the-money options cancelled for no consideration and in-the-money options accelerated and settled in shares
- · Pro forma figures are preliminary and subject to revision, including for additional financing and offering costs
10-11-2026
Texas Ventures Acquisition III Corp, a Cayman Islands blank check company, entered into an Amended and Restated Promissory Note dated November 8, 2026 with sponsor Yorkville Acquisition Sponsor II, LLC, increasing the principal amount to $750,000.00 from a prior $250,000.00 note via an additional advance of up to $500,000.00. The note is non-interest bearing, matures on the earlier of the initial business combination or winding up, and is optionally convertible into post-combination New Units at $10.00 per unit. The Payee waived claims against the IPO trust account, with repayment to come from trust proceeds released upon closing a business combination.
- · Note is non-interest bearing (0% interest)
- · Maturity Date is the earlier of consummation of initial business combination or effective winding up of the Maker
- · Conversion: principal converted divided by $10.00, rounded down to nearest whole New Unit
- · New Units carry same terms as private placement units issued with the IPO
- · Payee waived all claims against the IPO trust account; repayment to be made from trust proceeds released upon business combination
- · Note governed by New York law
- · Events of Default include payment failure (5 business-day cure), voluntary bankruptcy, and involuntary bankruptcy unstayed for 60 consecutive days
- · No individual officer, director, employee or shareholder is personally liable for the note
- · Note amends, restates and supersedes the Prior Note dated September 30, 2026 without novation
10-11-2026
Bunker Hill Mining Corp. completed its court-approved plan of arrangement to acquire all outstanding shares of Silver47 Exploration Corp., issuing 36,325,517 Bunker Hill Shares at an exchange ratio of 0.1724 per Silver47 Share, leaving 83,667,856 shares outstanding with legacy Bunker Hill and former Silver47 holders owning approximately 57% and 43% respectively. The combined company, to be renamed Bunker Hill Silver Corp., reports a pro forma basic market capitalization of US$158M and an aggregate resource inventory of 80 Moz AgEq measured and indicated plus 308 Moz AgEq inferred across four U.S. projects. However, the combined entity remains pre-commercial at the Bunker Hill Mine (commercial production targeted by end of 2026) and the +5 Moz AgEq annual production target is aspirational, with 2027 output of +2,500 koz AgEq based only on analyst consensus projections rather than company guidance.
- · Total reserves: 2.9 Mt at 35 g/t Ag, 5.8% Zn, 2.6% Pb for 34.2 Moz AgEq
- · Total indicated resources: 7.3 Mt at 52 g/t Ag, 340 g/t AgEq for 80.2 Moz AgEq
- · Total inferred resources: 28.3 Mt at 82 g/t Ag, 338 g/t AgEq for 308.1 Moz AgEq
- · Red Mountain inferred: 15.6 Mt at 71 g/t Ag, 0.4 g/t Au for 168.6 Moz AgEq
- · Hughes indicated: 1.0 Mt at 188 g/t Ag, 1.6 g/t Au for 10.3 Moz AgEq; inferred 3.7 Mt at 149 g/t Ag for 35.7 Moz AgEq
- · Mogollon inferred: 2.7 Mt at 139 g/t Ag, 2.7 g/t Au for 32.1 Moz AgEq
- · Mineral reserve estimates use zinc at US$1.20/lb, silver at US$20.00/oz, lead at US$1.00/lb
- · Silver47 to be delisted from TSXV, Frankfurt Stock Exchange and OTCQX on or about November 9, 2026, and to cease being a reporting issuer in Canada
- · Eventus to receive advisory fee in Bunker Hill Fee Shares subject to TSX approval and four-month-plus-one-day hold period
- · Arrangement Agreement dated August 20, 2026; proxy statement dated September 23, 2026; Silver47 circular dated September 24, 2026
- · Operational headquarters to be located at Bunker Hill Mine site in Silver Valley, Idaho
- · TSX has conditionally approved listing of the Bunker Hill Shares issued under the Arrangement
10-11-2026
Globa Terra Acquisition Corp (GTERU) filed an 8-K disclosing a special resolution amending its Articles to extend the deadline to complete an initial Business Combination. The Initial Expiry Date is extended one month to November 9, 2026, contingent on depositing US$0.03 per Public Share into the Trust Account, with the board able to further extend up to eight additional one-month periods by depositing the lesser of US$0.04 per non-redeemed Public Share per month or US$50,000 per month. Absent a Business Combination by the Deadline Date, the company must cease operations, redeem Public Shares within ten business days, and liquidate and dissolve.
- · Initial Expiry Date is 15 months from IPO consummation, extended one month to November 9, 2026 via the Initial Extension
- · Initial Extension Payment must be deposited within two business days following the general meeting and prior to any redemption of Public Shares
- · Board may further extend the deadline up to eight times by one month each without a shareholder vote
- · New Article 49.8A ensures all Public Shares in issue at the meeting date participate in the Initial Extension Payment regardless of redemption or voting
- · If the Special Resolution is not passed, no Initial Extension Payment shall be made
- · Redemption price equals aggregate Trust Account deposits including interest (less taxes payable and up to US$100,000 for dissolution expenses) divided by Public Shares outstanding
10-11-2026
Iron Horse Acquisition II Corp. (Nasdaq: IRHO) and Electra Vehicles, Inc. ("ELECTRA AI") announced the filing of Amendment No. 1 to the Form S-4 registration statement for their proposed business combination, reflecting SEC staff comments and including ELECTRA's unaudited financials for the six months ended June 30, 2026. ELECTRA also disclosed approximately $5 million in new bridge financing to support commercial execution. The deal, originally signed April 21, 2026 and amended May 14, 2026, is expected to close in Q1 2027 and list on Nasdaq under ticker "AIBR," subject to SEC effectiveness and shareholder approvals; no revenue, profitability, or valuation figures were disclosed in this filing.
- · Merger Agreement dated April 21, 2026, as amended May 14, 2026
- · Registration Statement includes ELECTRA's unaudited condensed consolidated financial statements for the six months ended June 30, 2026
- · Updated investor presentation filed with the SEC on November 2, 2026
- · Combined company expected to operate as ELECTRA AI, Inc. with Class A common stock on Nasdaq under ticker "AIBR"
- · Closing expected in Q1 2027, subject to SEC effectiveness, Iron Horse shareholder and ELECTRA stockholder approvals, and customary conditions
- · ELECTRA AI co-founded in 2015 by Fabrizio Martini, inspired by work as Principal Investigator on NASA projects
- · Target markets: Energy Infrastructure (BESS for grid, renewables, data centers), autonomous systems (robotics, humanoid, space assets), and e-mobility
- · IRHO 10-K for fiscal year ended November 30, 2025 filed February 13, 2026
- · No revenue, earnings, valuation, or redemption figures disclosed in this filing
10-11-2026
Live Oak Acquisition Corp. VI (Nasdaq: LOVIU), a blank-check company, filed an 8-K announcing that commencing November 13, 2026, holders of its IPO units may elect to separately trade the underlying Class A ordinary shares (LOVI) and redeemable warrants (LOVIW); unseparated units will continue trading as LOVIU. No fractional warrants will be issued and only whole warrants will trade. The filing contains no financial results, deal terms, or merger target — it is a routine post-IPO unit-separation notice, not an actual acquisition despite the preliminary 'Merger/Acquisition' tag.
- · Separate trading of shares and warrants commences November 13, 2026
- · Each unit consists of one Class A ordinary share and one-half of one redeemable warrant
- · No fractional warrants will be issued upon separation; only whole warrants will trade
- · Unseparated units continue trading under symbol LOVIU on Nasdaq
- · Holders must have their brokers contact transfer agent Continental Stock Transfer & Trust Company to separate units
- · Company is a blank check company (SIC 6770) incorporated in the Cayman Islands, EIN 98-1919679, SEC file number 001-43481
- · Company is an emerging growth company
- · Press release dated November 10, 2026 filed as Exhibit 99.1
Get daily alerts with 8 investment signals, 7 risk alerts, 7 opportunities and full AI analysis of all 8 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Merger & Acquisition SEC Filings
🇺🇸 More from United States
View all →November 12, 2026
US Pre-Market SEC Filings Roundup — November 12, 2026
US Pre-Market SEC Filings Roundup
November 11, 2026
US Pre-Market SEC Filings Roundup — November 11, 2026
US Pre-Market SEC Filings Roundup
November 11, 2026
All DOE Contracts — November 11, 2026
All DOE Contracts
November 11, 2026
All HHS Contracts — November 11, 2026
All HHS Contracts